On May 20, 2006, The Wall Street Journal (WSJ) ran a story about the drug choices available to people with RA. Reporter David Hamilton reviews the growing number of drug options now available to treat RA and provide relief to sufferers. While the emergence of new drugs in the market gives RA sufferers more options, there are also several challenges and risks linked to these drugs. High costs, complicated administration of the the drugs and potenitally deadly side effects are issues patients...
Read moreOn May 20, 2006, The Wall Street Journal (WSJ) ran a story about the drug choices available to people with RA. To read the story, visit... Read more »
On December 19, 2006, the United States Food and Drug Administration issued an “Alert” regarding the safety of Rituxan use in patients... Read more »
October is the beginning of flu season and medical offices, hospitals and clinics, schools and employers around the country are now... Read more »
It is very common for a woman with rheumatoid arthritis to suffer a disease flare within three months of the delivery of the baby. ... Read more »
The recent meeting of the European League Against Rheumatism (EULAR) continued to present more data on the tumor necrosis factor (TNF)... Read more »
A new rheumatoid arthritis (RA) medication being tested by Regeneron Pharmaceuticals and Sanofi has shown positive results in a recent clinical... Read more »
A review of previous studies has found a link between the use of tumor necrosis factor (TNF) inhibitors such as Remicade (infliximab), Enbrel... Read more »
According to a new study, tumor necrosis factor (TNF) inhibitors and the antimalarial medication hydroxychloroquine used by many patients with... Read more »
A new medication called fostamatinib has shown promise in a new study, researchers say. The drug is one of a new class of drugs known as spleen... Read more »
The U.S. Food and Drug Administration (FDA) has approved a new drug for people who suffer from arthritis related to immune-system disorders. The... Read more »